ADENOPROSIN – A DRUG WITH PATHOGENIC ACTION IN DISEASES OF THE PROSTATE GLAND. EXPERIMENTAL STUDY
Keywords:Adenoprosin, experimental model prostatitis, treatment of benign pathology of the prostate
Introduction. Prostate diseases, known and treated since ancient times, remain a major and controversial problem of urology. Etiopathologic theories of benign prostate disease have undergone major changes over the last decade. Hormonal involvement in the pathogenesis of benign prostatic hyperplasia is no longer considered paramount, the essential role in the occurrence and progression of hyperplasia being attributed to inflammatory processes.
The study aimed to review, in the light of new scientific theories, the anti-inflammatory activity of Adenoprosin, rectal suppositories 150 mg, on an experimental model of aseptic prostatitis compared to placebo.
Material and methods. The study was conducted based on the analysis of literature data on the role of inflammation in benign prostatic hyperplasia and the experimental compartment performed on 80 male white rats, in the Wistar line. The Adenoprosin drug, rectal suppositories 150 mg, was tested compared to placebo in models of acute and chronic abacterial prostatitis. In acute prostatitis, the drug was administered for 7 days, and in chronic prostatitis 15 days. Treatment efficacy criteria consisted of assessing general condition, prostate weight, and inflammatory and proliferative histological changes.
Results. In rats administered adenoprosin, the severity of the inflammatory process, in both acute and chronic abacterial prostatitis, was reduced. The surface of epithelial cells in the stromal area of the prostate was restored, decreasing the level of vascular congestion and decreasing epithelial desquamation. The histological picture of the prostate post-treatment was close to that of healthy rats, unlike rats given placebo where venous congestion and signs of inflammatory proliferation remained.
Conclusions. The entomological origin Adenoprosin drug, rectal suppositories 150 mg, demonstrated an obvious anti-inflammatory effect in the experimental model of acute aseptic or chronic abacterial induced prostatitis on Wistar line rats, significantly compared with Placebo (р<0,05).
The study opens new perspectives on pathogenesis and methods of treatment of benign pathologies of the prostate.
Copyright (c) 2023 Arta Medica
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.